The objective of this contract is to utilize a next-generation vaccine adjuvant that induces rapid and serum-stable spontaneous nanoliposome-antigen particleization in combination with multiple native…
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93019C00011
- Awardee
-
Pop Biotechnologies Inc. UEI ZWKMU75DGJY4
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $599,897
Award facts
- Opportunity
-
- SBIRPHS20191 Solicitation number
- Nanoparticle Delivery of HIV Env Trimer for Inducing Somatic Hypermutation and bNAb Award Notice · Posted Jun 29, 2018
- Contract value 100% obligated
- $599,897.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 9 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Amherst, NY 14228, USA
- Research
- SBIR Program Phase I Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $599,897 |
About this award
This is a $599,897 firm fixed price definitive contract between the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) and Pop Biotechnologies Inc., a Buffalo, NY-based biotechnology company. The objective of this Small Business Innovation Research (SBIR) Program Phase I contract is for Pop Biotechnologies to utilize a next-generation vaccine adjuvant to induce rapid and serum-stable spontaneous nanoliposome-antigen particleization in combination with multiple native flexibly linked HIV envelope trimers, with the goal of inducing high levels of virus-neutralizing antibodies following immunization. This contract supports Pop Biotechnologies' research and development efforts to address unmet medical needs in infectious disease.
Description
The objective of this contract is to utilize a next-generation vaccine adjuvant that induces rapid and serum-stable spontaneous nanoliposome-antigen particleization in combination with multiple native flexibly linked (NFL) HIV envelope trimers to induce high level of virus-neutralizing antibodies following immunization.
Quick answers
Who was awarded contract 75N93019C00011?
75N93019C00011 was awarded to Pop Biotechnologies Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 17, 2019.
How much is contract 75N93019C00011 worth?
The government has obligated $599,897 on 75N93019C00011.
Was contract 75N93019C00011 competed?
The extent of competition for 75N93019C00011 was full and open competition after exclusion of sources. The government received 9 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award